Total Payments
$7,261
2024 Payments
$1,354
Companies
42
Transactions
181
Medicare Patients
319
Medicare Billing
$64,063
Payment Breakdown by Category
Food & Beverage$7,096 (97.7%)
Education$164.99 (2.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,096 | 179 | 97.7% |
| Education | $164.99 | 2 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $925.44 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $758.92 | 11 | $0 (2024) |
| GENZYME CORPORATION | $501.43 | 9 | $0 (2024) |
| Lilly USA, LLC | $482.07 | 19 | $0 (2024) |
| Celgene Corporation | $466.91 | 6 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $373.67 | 5 | $0 (2024) |
| Seagen Inc. | $368.73 | 3 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $318.85 | 14 | $0 (2024) |
| Exelixis Inc. | $272.60 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $254.16 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,354 | 56 | Lilly USA, LLC ($175.27) |
| 2023 | $1,307 | 53 | Lilly USA, LLC ($202.64) |
| 2022 | $815.14 | 24 | JAZZ PHARMACEUTICALS INC. ($388.12) |
| 2021 | $2,413 | 32 | GENZYME CORPORATION ($443.16) |
| 2020 | $265.19 | 4 | Alexion Pharmaceuticals, Inc. ($124.83) |
| 2019 | $1,079 | 11 | AstraZeneca Pharmaceuticals LP ($243.19) |
| 2018 | $27.38 | 1 | Amgen Inc. ($27.38) |
All Payment Transactions
181 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $27.32 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Oncology | ||||||
| 10/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $34.77 | General |
| 10/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $1.14 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Oncology | ||||||
| 10/14/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Oncology | ||||||
| 10/03/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/06/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $19.44 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/30/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Oncology | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.79 | General |
| Category: Hematology/Oncology | ||||||
| 08/23/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: BioOncology | ||||||
| 08/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Oncology | ||||||
| 08/14/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Oncology | ||||||
| 08/09/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 308 | 2,280 | $212,525 | $62,473 |
| 2022 | 1 | 11 | 11 | $4,399 | $1,590 |
Total Patients
319
Total Services
2,291
Medicare Billing
$64,063
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 67 | $33,433 | $9,834 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 53 | 53 | $32,317 | $9,645 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 88 | $31,328 | $9,179 | 29.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 1,560 | $35,880 | $8,833 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 112 | $28,336 | $8,312 | 29.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 112 | $21,392 | $7,424 | 34.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 31 | $16,430 | $4,504 | 27.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 24 | $6,744 | $2,393 | 35.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 101 | $4,949 | $1,259 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 45 | 132 | $1,716 | $1,089 | 63.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $4,399 | $1,590 | 36.1% |
About Dr. Christopher Foss, MD
Dr. Christopher Foss, MD is a Hospitalist healthcare provider based in Santa Clarita, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2016. The National Provider Identifier (NPI) number assigned to this provider is 1629431044.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Foss, MD has received a total of $7,261 in payments from pharmaceutical and medical device companies, with $1,354 received in 2024. These payments were reported across 181 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($7,096).
As a Medicare-enrolled provider, Foss has provided services to 319 Medicare beneficiaries, totaling 2,291 services with total Medicare billing of $64,063. Data is available for 2 years (2022–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Hematology & Oncology
- Location Santa Clarita, CA
- Active Since 04/02/2016
- Last Updated 03/13/2025
- Taxonomy Code 208M00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629431044
Products in Payments
- DEFITELIO (Drug) $519.43
- LYNPARZA (Drug) $513.40
- VERZENIO (Drug) $410.71
- SARCLISA (Biological) $363.88
- ADCETRIS (Biological) $246.83
- RYLAZE (Drug) $231.48
- Nubeqa (Drug) $220.99
- Cabometyx (Drug) $217.28
- JAKAFI (Drug) $194.17
- VENCLEXTA (Drug) $173.66
- VYXEOS (Drug) $143.07
- Inrebic (Drug) $139.58
- Ultomiris (Drug) $125.21
- IMFINZI (Biological) $125.00
- PADCEV (Biological) $121.90
- DARZALEX (Biological) $119.81
- Blincyto (Biological) $119.64
- TEGSEDI (Drug) $118.80
- ELITEK (Biological) $117.10
- Tecentriq (Biological) $113.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.